ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.
Epistemonikos ID: 33486ea5937bbfeaed4dc0eb41c5e4b5e0ee14e3
First added on: May 09, 2024